![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Rilpivirine Week 96 safety and efficacy by gender and race subgroups in treatment-naïve HIV-1-infected patients in the Phase III ECHO and THRIVE trials
|
|
|
Reported by Jules Levin IDSA Boston, MA Oct 20-22 2012
Claudia Martorell,1 Cynthia A Mayer,2 Esteban Ribera,3 Armin Rieger,4 Sharon Walmsley,5 Simon Vanveggel6 and Katia Boven7
1The Research Institute, Springfield, MA, USA; 2St. Joseph's Comprehensive Research Institute, Tampa, FL, USA; 3Hospital Vall D'Hebrón, Barcelona, Spain; 4Medical University of Vienna, Vienna, Austria; 5University Health Network, Toronto, ON, Canada; 6Tibotec BVBA, Beerse, Belgium; 7Tibotec Inc., Titusville, NJ, USA
![Conclusion.gif](../images/102411/102411-2/Conclusion.gif)
![IDSA2.gif](../images/102411/102411-2/IDSA2.gif)
![IDSA3.gif](../images/102411/102411-2/IDSA3.gif)
![IDSA4.gif](../images/102411/102411-2/IDSA4.gif)
![IDSA5.gif](../images/102411/102411-2/IDSA5.gif)
![IDSA6.gif](../images/102411/102411-2/IDSA6.gif)
![IDSA7.gif](../images/102411/102411-2/IDSA7.gif)
![IDSA8.gif](../images/102411/102411-2/IDSA8.gif)
![IDSA9.gif](../images/102411/102411-2/IDSA9.gif)
![IDSA10.gif](../images/102411/102411-2/IDSA10.gif)
![IDSA11.gif](../images/102411/102411-2/IDSA11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|